Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for October 2022

Oslo, Norway, November 9, 2022 Commercial update: In October 2022, the Company achieved average time charter equivalent earnings of approximately US$26,700 per day, gross. The Company’s five vessels trading on index-linked time charter earned approximately US$25,100 per day, gross, including average daily scrubber benefits of approximately US$2,600 per day. The Company’s three vessels trading on fixed time charter earned approximately US$28,900 per day, gross, including average daily scrubber benefits of approximately US$3,700 per day. The Baltic 5TC Capesize Index averaged US$17,

2020 Bulkers Ltd. (2020) - Results for the third quarter of 2022

Oslo, Norway, November 9, 2022 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and nine months ended September 30, 2022. Key events during the third quarter of 2022 · The Company reported net profit of US$7.3 million and EBITDA of US$12.7 million for the third quarter of 2022. · Achieved average time charter equivalent earnings of approximately US$25,800 per day, gross. · The Company declared total cash distributions of US$0.30 per share for the months of July, August and September 2022.

FDA Advisory Committee recommends PT027 in asthma

9 November 2022 07:00 GMT PT027 recommended by FDA advisory committee as new rescue treatment for asthma First and only rescue medication recommended for US approval that has been shown to reduce severe exacerbations The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8 that the data do not support a

Invitation to presentation of Catena Media’s Q3 results 2022

Catena Media’s interim report for the third quarter that ended 30 September 2022 will be published in English on Thursday 17 November at 07:00 CET. Following the report’s release, a combined presentation audiocast and telephone conference with the opportunity to ask questions will be held at 10:00 CET on the same day, with CEO Michael Daly and Group CFO Peter Messner presenting the report. The audiocast will be accessible via the following link:https://ir.financialhearings.com/catena-media-q3-2022 The presentation will also be available on the company’s website:https://www.

Interim report 1 January – 30 September 2022

Halmstad, 9 November 2022third QUARTER (1 July – 30 September 2022) · Net sales for the quarter amounted to MSEK 917 (180). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 713 (76). · Operating profit (EBIT) totalled MSEK 697 (61). · Profit before tax, before items affecting comparability totalled MSEK 722 (57), and after items affecting comparability MSEK 705 (54). · Profit after tax amounted to MSEK 705 (54), or SEK 15.86 (1.41) per share. · Operating cash flow was MSEK 792 (93) and cash flow after investments amounted to MSEK 659 (64).

Karnov Group reports third quarter results 2022

Extraordinarily strong growth and all clear for European expansionFinancial highlights third quarter · Net sales increased by 18.4% to SEK 263 m (222), organic growth was 13.2% and acquired growth accounted for 2.4%. Currency effect was 2.8%. · EBITA amounted to SEK 85 m (80) with EBITA margin of 32.4% (36.1%). Items affecting comparability amounted to SEK 8 m (8). · Adjusted EBITA amounted to SEK 93 m (88) with adjusted EBITA margin of 35.3% (39.5%). · Net result amounted to SEK 50 m (23). · Earnings per share before and after dilution amounted to SEK 0.46 (0.24). ·

EQT Ventures III closes Europe's largest venture capital fund committed to early-stage tech startups

· EQT Ventures III holds final close at EUR 1 billion of fee-generating commitments, and EUR 1.1 billion of total commitments, to invest in European and North American early-stage tech startups  · The Fund, which includes participation from a wide range of European, North American and Asian institutional investors, foundations, and endowments, will make investments of EUR 1-50 million in founder-led startups using technology to try and solve some of the biggest challenges facing society  · EQT Ventures III brings total commitments raised across the EQT Ventures Funds to EUR 2.3

Last day of subscription of units in DanCann Pharma A/S ongoing rights issue and guidance on how to subscribe

COPENHAGEN, Denmark, November 09, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that Friday, November 11th, 2022, is the last day for subscription in DanCann Pharma’s ongoing rights issue of units of approximately DKK 28.5 million (the "Rights Issue").The last day of trading in unit rights on Spotlight Stock Market is today, the 9th of November 2022. Note that some banks and brokers have an earlier date for subscription than the 11th of November. Current shareholders or new investors should therefore

Huayou Cobalt awards tailings filtration equipment order to Metso Outotec

Metso Outotec Corporation’s press release on November 9, 2022, at 09:00 a.m. EETMetso Outotec has been awarded a repeat order to deliver sustainable tailings filtration technology for Zhejiang Huayou Cobalt Co. Ltd.’s new laterite nickel mine project in Indonesia. The order value, which is not disclosed, has been booked in Minerals fourth-quarter 2022 orders received. Metso Outotec’s scope of delivery consists of the engineering, manufacturing and supply of 15 Larox® FFP3512 filters, as well as installation and commissioning advisory services and spare parts. The fully automatic, fast-

Property transaction between Balder and Circle K enables 1,000 new homes and the opportunity for Circle K to test new ideas in central Kungsbacka

Fastighets AB Balder has acquired a property of approximately 4,600 sqm from Circle K and is a step closer to realising the Sydöstra Centrum urban development project in Kungsbacka. The building plans include housing, commercial premises and the possibility to establish a new type of fossil-free fuel station in central Kungsbacka.Through the Sydöstra Centrum area, Balder wants to create a modern, attractive and natural extension of Kungsbacka town centre. Circle K recently sold its share of the land to Balder but it has no plans to leave the area. Instead the establishment is planned at the

Neste to offer public electric vehicles charging service at its stations in Finland to complement its portfolio of solutions to reduce transport emissions

Neste Corporation, Press Release, 9 November 2022 at 9.00 a.m. EETNeste is introducing public high power charging (HPC) at its service stations in Finland for light and medium-duty electric vehicles. Neste MY Renewable Charging™ adds another option to Neste’s portfolio of solutions in Finland for supporting the transition to low-emission transport.  Serving both business and consumers, Neste’s first public high power charging stations will become available at the turn of the year at Neste Hankasalmi Jari-Pekka and Neste Oulunbaari Maikkula service stations. Furthermore, Neste

Swedish Stirling AB: Q3, 2022 report

Swedish Stirling AB publishes its Q3, 2022 report today.Swedish clean tech company Swedish Stirling AB is publishing its interim report for the period 01-07-2022 – 30-09-2022 today. The report is available for download in its entirety on the company’s website. Significant events during the period include the following: · Net sales for the quarter amounted to TSEK 39 (TSEK 50). Total revenue and capitalized work for the quarter was TSEK 39 (TSEK 10,666). · Earnings per share, before dilution, for the quarter was SEK -1.90 (SEK -0.13). · The Board of Directors of Swedish

Skanska signs a EUR 500,000,000 sustainability linked revolving credit facility

On Tuesday, 8 November 2022, Skanska entered into a new EUR 500,000,000 multicurrency revolving credit facility linked to its sustainability goals. The Facility has a tenor of five years with two one year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017. The interest rate margin on the credit facility is linked to Skanska’s sustainability strategy. The KPIs relates to Skanska’s ambitious climate targets which have been validated by the Science Based Targets

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseNovember 9, 2022, at 9.00 am EETRepurchase of Outokumpu’s own shares On November 8, 2022, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |81,253 |4.7763

Quickbit publishes Q1 interim report ‘22/23

Quickbit reports sales of SEK 68.1 million in Q1 ’22/23. A rising sales volume was noted toward the end of the quarter, which is expected to continue into Q2 ’22/23. As the result of continued cost efficiency enhancements and a balanced product mix, the gross margin amounted to 4.2%. Full focus on the new products Quickbit Pay and Quickbit Checkout ahead of their broad launch before the year end.First quarter, July – September 2022 in summary · Net sales totalled €68.1 million (97.1). · Gross profit amounted to €2.9 million (3.6) with a gross margin of 4.2% (3.7). · Adjusted

Oncopeptides publishes Q3 report 2022

STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022.“The successful directed share issue in July and the approval of Pepaxti[®] in EU and EEA-countries in August, set the stage for a new and exciting phase for Oncopeptides,” says Jakob Lindberg, CEO of Oncopeptides. “With the ongoing launch in Germany we are entering a European market with potential revenue of approximately 1.5-2.0 billion SEK,

Changes in Solteq Plc’s Executive Team

Stock Exchange Bulletin, November 9, 2022, at 9:00 a.m. VP of People and Culture of Solteq Plc and a member of the Executive Team, Kirsi Jalasaho, has announced her resignation to assume a new position outside of Solteq. Jalasaho will continue in her current position and as a member of the Executive Team until the end of January 2023. The company will at once start a process for finding a new VP of People and Culture.  “I wish to express, on behalf of the entire company, my gratitude to Kirsi for her significant contribution to the development of human resources administration and

Gaming Innovation Group reports Q3 2022

Gaming Innovation Group Inc. (GiG) reports Q3 2022 revenues* of €22.9 million and an adjusted EBITDA of €8.5 million.  “I am pleased with the development and performance of GiG over the third quarter. The business delivered another record quarter with revenue growth up 35% year-over-year”, says Richard Brown, CEO of GiG.  Financial Highlights · All time high revenues* in Q3 2022 of €22.9m (16.9), an increase of 35% YoY, whereof 24% organic  · Adjusted EBITDA was €8.5m (5.8), up 47%, adjusted EBITDA margin* increased to 37.0% (34.1) · EBIT was €2.5m (2.1), with an EBIT

Oncopeptides announces the market potential for Pepaxti in Europe

STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential for Pepaxti[®] in Europe. The potential assumes that the Company´s pending type 2 variation submission to the European Medicines Agency based on OCEAN data, will be approved by the agency, and enable patients with relapsed refractory multiple myeloma access to the drug in an earlier treatment line. Furthermore, the market potential assumes that price

Lundbeck’s sales increased by 11% (+6% in local currencies) to DKK 13.6 billion in the first nine months of 2022

HIGHLIGHTS Growth of Lundbeck’s strategic brands accelerates further growing 30% (+19% in local currencies) in the first nine months of 2022 thereby reaching DKK 8.8 billion, representing 65% of overall revenue. · Brintellix[®]/Trintellix[®]: +24% reported to DKK 3,177 million (+15% in local currencies) · Rexulti[®]/Rxulti[®]: +33% reported to DKK 2,817 million (+19% in local currencies) · Abilify Maintena[®]: +20% reported to DKK 2,164 million (+13% in local currencies) · Vyepti[®]: +105% reported to DKK 672 million (+82% in local currencies) All markets contribute to

Toivo Group Plc’s business review 1 January–30 September 2022: Operating profit almost doubled to EUR 18.0 (9.9) million, growth of 81%*. Occupancy rate 98.7%.

Business Review, 9. November 2022 at 8:30   * Unaudited   FINANCIAL PERIOD 1 JANUARY–30 SEPTEMBER 2022 KEY EVENTS · Operating profit MEUR 18.0 (9.9). · Contracts for building a total of 302 (650) apartments were made during the period under review. · 417 (464) apartment start-ups during the period under review. · 309 (112) apartments were completed during the period under review.   PROSPECTS FOR 2022 UNCHANGED · The company expects the operating profit of the financial year of 1 January–31 December 2022 to be EUR 22–28 million. (Unchanged) · The

Interim report January–September 2022 Nordax Bank AB

Highlights January–September 2022 · Total lending amounted to SEK 83.9 billion (SEK 70.7 billion as at 31 December 2021) · Personal loans and credit cards amounted to SEK 68.9 billion (SEK 58.0 billion as at 31 December 2021) · Mortgage lending (mortgage loans and equity release mortgages) amounted to SEK 14.9 billion (SEK 12.7 billion as at 31 December 2021), comprising 18% of total lending · Nordax’s savings offering continued to grow and total deposits amounts to SEK 72.0 billion (SEK 67.4 billion as at 31 December 2021) · Operating profit amounted to SEK 1,252 million (

Interim report January–September 2022 Nordax Holding AB

Highlights January–September 2022 · Total lending amounted to SEK 84.5 billion (SEK 71.4 billion as at 31 December 2021) · Personal loans and credit cards amounted to SEK 69.6 billion (SEK 58.7 billion as at 31 December 2021) · Mortgage lending (mortgage loans and equity release mortgages) amounted to SEK 14.9 billion (SEK 12.7 billion as at 31 December 2021), comprising 18% of total lending · Nordax’s savings offering continued to grow and total deposits amounts to SEK 72.0 billion (SEK 67.4 billion as at 31 December 2021) · Operating profit amounted to SEK 1,149 million (

BPC receives significant order of six complete AMPTS[®] systems

BPC Instruments AB (“BPC” or the “Company”) has received two succession purchase orders from a UK-based green energy supplier for the delivery of six complete AMPTS[®] systems with a total order value of over 130 000 Euro.BPC has received a significant order of six complete systems of the Company’s flagship product AMPTS[®]. The order, with a total order value of over 130 000 Euro, comes from a UK-based green energy supplier. The revenue of the latest purchase will be reflected in the fourth quarter. Since the beginning of 2022, BPC Instruments has received a significant increase in

There are no items matching the current filter
There are no more items matching the current filter
Back to top